$7.23
7.66%
Nasdaq, Tue, Aug 12 2025
ISIN
US30234E1047
Symbol
EYEN

Eyenovia, Inc. Stock price

$7.23
-4.80 39.90% 1M
+5.38 290.81% 6M
-4.45 38.10% YTD
-63.01 89.71% 1Y
-129.57 94.71% 3Y
-400.77 98.23% 5Y
-786.37 99.09% 10Y
-786.37 99.09% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
-0.60 7.66%
ISIN
US30234E1047
Symbol
EYEN

Key metrics

Basic
Market capitalization
$45.6m
Enterprise Value
$51.7m
Net debt
$6.1m
Cash
$3.9m
Shares outstanding
2.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
651.5 | 10.2
EV/Sales
738.2 | 11.6
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-357.1%
Return on Equity
380.4%
ROCE
332.2%
ROIC
-
Debt/Equity
-1.0
Financials (TTM | estimate)
Revenue
$70.0k | $4.5m
EBITDA
$-29.5m | $-70.0m
EBIT
$-30.3m | $-33.5m
Net Income
$-42.4m | $-95.8m
Free Cash Flow
$-24.7m
Growth (TTM | estimate)
Revenue
600.0% | 7,335.0%
EBITDA
1.2% | -92.4%
EBIT
-0.3% | 10.8%
Net Income
-30.6% | -92.4%
Free Cash Flow
14.4%
Margin (TTM | estimate)
Gross
-5,450.4%
EBITDA
-43,983.9% | -1,570.1%
EBIT
-45,147.8%
Net
-63,159.3% | -2,148.3%
Free Cash Flow
-36,769.2%
More
EPS
$-19.4
FCF per Share
$-8.7
Short interest
4.0%
Employees
14
Rev per Employee
$0.0
Show more

Is Eyenovia, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Financial data from Eyenovia, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
0.07 0.07
600% 600%
100%
- Direct Costs 3.72 3.72
37,100% 37,100%
5,314%
-3.66 -3.66
-
-5,229%
- Selling and Administrative Expenses 13 13
2% 2%
18,671%
- Research and Development Expense 9.92 9.92
32% 32%
14,171%
-30 -30
1% 1%
-42,157%
- Depreciation and Amortization 0.78 0.78
136% 136%
1,114%
EBIT (Operating Income) EBIT -30 -30
0% 0%
-43,277%
Net Profit -42 -42
31% 31%
-60,543%

In millions USD.

Don't miss a Thing! We will send you all news about Eyenovia, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Eyenovia, Inc. Stock News

Neutral
PRNewsWire
about 2 months ago
NEW YORK , June 18, 2025 /PRNewswire/ -- Chardan, a leading global investment banking and advisory firm, today announced an expansion into the digital asset sector, advising on and structuring a series of transactions that bridge traditional capital markets with the rapidly evolving world of blockchain and cryptocurrency. As part of its strategic push into crypto finance, Chardan has recently s...
Neutral
GlobeNewsWire
about 2 months ago
EYEN to bring on major Hyperliquid Thought Leader to support HYPE Treasury Strategy EYEN to bring on major Hyperliquid Thought Leader to support HYPE Treasury Strategy
Positive
Market Watch
about 2 months ago
Eyenovia shares more than doubled as the company entered a $50 million investment agreement and said it plans to launch a hyperliquid cryptocurrency treasury reserve strategy.
More Eyenovia, Inc. News

Company Profile

Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine. The firm is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression and mydriasis. The company was founded by Sean Ianchulev on March 12, 2014 and is headquartered in New York, NY.

Head office United States
CEO Michael Rowe
Employees 14
Founded 2014
Website eyenovia.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today